Výsledky vyhledávání

Akademický článek

Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Autor: Barlaam B; IMED Oncology, AstraZeneca, Darwin Building, Cambridge Science Park, 319 Milton Road, Cambridge CB4 0WG, United Kingdom. Electronic address: bernard.barlaam2@astrazeneca.com., Cosulich S; IMED Oncology, AstraZeneca, Darwin Building, Cambridge Science Park, 319 Milton Road, Cambridge CB4 0WG, United Kingdom., Degorce S; IMED Oncology, AstraZeneca, Darwin Building, Cambridge Science Park, 319 Milton Road, Cambridge CB4 0WG, United Kingdom., Ellston R; IMED Oncology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Fitzek M; IMED Oncology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Green S; IMED Oncology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Hancox U; IMED Oncology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lambert-van der Brempt C; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Lohmann JJ; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Maudet M; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Morgentin R; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Plé P; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Ward L; IMED Oncology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Warin N; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2017 May 01; Vol. 27 (9), pp. 1949-1954. Date of Electronic Publication: 2017 Mar 14.

Zobrazit plný text záznamu

Akademický článek

Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Autor: Barlaam B; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Cosulich S; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Degorce S; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Fitzek M; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Green S; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Hancox U; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lambert-van der Brempt C; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Lohmann JJ; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Maudet M; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Morgentin R; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Péru A; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Plé P; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Saleh T; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Ward L; AstraZeneca Pharmaceuticals, Oncology iMed, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Warin N; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2016 May 01; Vol. 26 (9), pp. 2318-23. Date of Electronic Publication: 2016 Mar 11.

Zobrazit plný text záznamu

Akademický článek

Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.

Autor: Barlaam B; Centre de Recherches, AstraZeneca , Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France., Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Pasquet MJ, Péru A, Plé P, Saleh T, Vautier M, Walker M, Ward L, Warin N

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2015 Jan 22; Vol. 58 (2), pp. 943-62. Date of Electronic Publication: 2015 Jan 07.

Zobrazit plný text záznamu

Akademický článek

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.

Autor: Delouvrié B; AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France. benedicte.delouvrie@astrazeneca.com, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Jun 15; Vol. 22 (12), pp. 4111-6. Date of Electronic Publication: 2012 Apr 21.

Zobrazit plný text záznamu

Akademický článek

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Jun 15; Vol. 22 (12), pp. 4117-21. Date of Electronic Publication: 2012 Apr 21.

Zobrazit plný text záznamu

Akademický článek

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Autor: Mortlock AA; AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2007 May 03; Vol. 50 (9), pp. 2213-24. Date of Electronic Publication: 2007 Mar 21.

Zobrazit plný text záznamu

Akademický článek

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

Autor: Jung FH; AstraZeneca, Centre de Recherches, Parc Industriel Pompelle, BP1050, Chemin de Vrilly, 51689 Reims Cedex 2, France. Frederic.Jung@astrazeneca.com, Pasquet G, Lambert-van der Brempt C, Lohmann JJ, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2006 Feb 09; Vol. 49 (3), pp. 955-70.

Zobrazit plný text záznamu

Akademický článek

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Autor: Hennequin LF; AstraZeneca, Zeneca Pharma, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims Cedex 2, France., Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C

Publikováno v: Journal of medicinal chemistry [J Med Chem] 1999 Dec 30; Vol. 42 (26), pp. 5369-89.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání